Opus Genetics’ (IRD) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Opus Genetics (NASDAQ:IRD) in a research note published on Wednesday,Benzinga reports. They currently have a $8.00 target price on the stock.

Opus Genetics Trading Up 1.8 %

Shares of IRD opened at $1.12 on Wednesday. The company has a 50 day moving average price of $1.15. Opus Genetics has a twelve month low of $0.81 and a twelve month high of $2.65. The firm has a market capitalization of $35.36 million, a P/E ratio of -1.03 and a beta of 0.16.

Insider Buying and Selling

In related news, CEO George Magrath acquired 100,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 26th. The stock was purchased at an average cost of $0.98 per share, with a total value of $98,000.00. Following the transaction, the chief executive officer now directly owns 599,150 shares of the company’s stock, valued at $587,167. This trade represents a 20.03 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 6.60% of the stock is owned by company insiders.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.